Li Shuchan, Zhang Enfan, Cai Zhen
Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, No. 79, Qingchun Road, Hangzhou, Zhejiang, China.
Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, China.
Biomark Res. 2023 Mar 8;11(1):27. doi: 10.1186/s40364-023-00469-6.
Multiple myeloma (MM) is an incurable hematological cancer with high spatial- and temporal-heterogeneity. Invasive single-point bone marrow sampling cannot capture the tumor heterogeneity and is difficult to repeat for serial assessments. Liquid biopsy is a technique for identifying and analyzing circulating MM cells and cell products produced by tumors and released into the circulation, allowing for the minimally invasive and comprehensive detection of disease burden and molecular alterations in MM and monitoring treatment response and disease progression. Furthermore, liquid biopsy can provide complementary information to conventional detection approaches and improve their prognostic values. This article reviewed the technologies and applications of liquid biopsy in MM.
多发性骨髓瘤（MM）是一种无法治愈的血液系统癌症，具有高度的时空异质性。侵入性单点骨髓采样无法捕捉肿瘤异质性，且难以重复进行系列评估。液体活检是一种用于识别和分析循环中的MM细胞以及肿瘤产生并释放到循环中的细胞产物的技术，能够对MM的疾病负担和分子改变进行微创且全面的检测，并监测治疗反应和疾病进展。此外，液体活检可为传统检测方法提供补充信息，提高其预后价值。本文综述了液体活检在MM中的技术及应用。
